IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
RMDL: Classification of Parkinson's disease by nature-inspired Algorithm
Antidiabetic activity (In vitro alpha amylase inhibitory) of ethanol extract of Carissa carandas Linn. roots.
Six sigma: an embellished exploration in the field of pharmaceutical industry
The effect of Sida acuta on bacterial enzymes in azoxymethane-induced experimental colon cancer
Premature ageing in children: a rare genetic disorder called progeria.
Stress, Depression & Gut Microbiota: The Gut-Brain Axis Regulation
Zinc oxide nanoparticles and antibiotics mediated combinatorial approach to enhance antibacterial potential
Quality of life and associated factors among students in Jambi Province, Indonesia
Novel method for simultaneous determination of spiramycin and metronidazole in pharmaceutical dosage form by UV-visible absorption spectrophotometry
The Influence of Physicians Social Capital on Patients Satisfaction
1234
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
In vitro efficacy of anti-HSV drugs on breast cancer cells MCF-7 & MDA-MB- 231 - A drug repurposing approach

Author: VASUDHA ANISETTY, ASHISH WADHWANI, DIVYABHARATHI MANI, PRAVEEN T.K, VIRAL PATEL, SRIKANTH JUPUDI
Abstract: Breast cancer, a most common cancer in the women worldwide representing about quarter (25%) of all cancers. The predictions of cancer prevalence show an imperative need for strengthening the present diagnostic/treatment facilities. One such strategy to overcome the treatment burden for the breast cancer is drug repurposing/repositioning. This concept has been growing its importance, the very reason behind this is it decreases significantly the funds needed for the development of therapy for a disease and it increases the chances of the new indications from Phase I to entry in the market. The objective of the study was to evaluated the morphological characteristic, migration features of the cells and cell cycle arrest of the anti-HSV drug Acyclovir against breast cancer cell lines MCF-7 and MDA-MB231. The in vitro cytotoxicity studies, fragmentation assay, long term clonogenic assay and cell cycle analysis were carried out in the study. In MTT assay acyclovir showed IC50 of 3.16 ± 1.10µg/ml and 3.85 ± 1.54µg/ml respectively with SI of 33.46 tested against MCF-7 and MDAMB-231 cell lines. The platting efficiency was found to be 52.30 % by clonogenic assay. One of the indications of cell death by apoptosis is accumulation of cells in G2/M phase which was observed with Acyclovir in cell cycle analysis. The study showed that Acyclovir inhibited cancer cells propagation, colony formation ability and cell cycle arrest at G2/M phase, while having no effect on the normal cells. These results indicated new insights on the effect of anti-HSV agents on the tumorigenesis and metastasis.
Keyword: Acyclovir; Antiviral; Breast cancer; Drug repurposing/repositioning
DOI: https://doi.org/10.31838/ijpr/2020.12.02.0056
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free